

CALL FOR PAPERS

Evaluating Genomic and Precision Medicine

Value in Health

Advances in genomic and precision medicine are transforming healthcare delivery and creating new opportunities and evidence needs for health systems worldwide. Genomic medicine refers to the use of information from an individual's genome to inform the prevention, screening, diagnosis, and treatment of disease. Precision medicine builds on insights derived from genomic information to tailor prevention and treatment strategies to individual patients. Emerging applications—including polygenic risk scores, genomic newborn screening, pharmacogenomic testing, gene therapies, and gene editing—are expanding the potential impact of genomics across the life cycle.

As genomic and precision medicine enters routine clinical care, methods for evaluating their effects on patients, families, providers, payers, and health systems are also advancing. This rapidly evolving field raises important questions about evidence generation, valuation, reimbursement, implementation, and equity.

For this themed section, the Guest Editors invite conceptual, empirical, methodological, or policy-oriented submissions that evaluate genomic and precision medicine. We welcome original research, critical reviews and systematic reviews, and methodological papers addressing challenges and opportunities in global healthcare settings.

Topics of interest include, but are not limited to:

Genomic Medicine and Genomic Sequencing

- Methods to evaluate the long-term patient-centered, behavioral, and health system-level impacts of genomic diagnostics and screening programs
- Methodological advances and applied research that integrate equity into decision-making frameworks for genomic technologies
- Economic evaluations of genomic sequencing applications, including preventive genomics, carrier and cell-free DNA screening, newborn screening, and genomic risk stratification
- Approaches to measuring clinical utility, health outcomes, equity effects, and opportunity costs associated with genomic testing and genomically informed care
- Methods for incorporating patient and family preferences, experiences, and outcomes into economic evaluations and value assessments of genomic technologies

Precision Medicine and Genomic Therapeutics

- Implications of genomic technologies for regulatory evaluation, health technology assessment, reimbursement, and value assessment frameworks
- Methods and measures for assessing the value of precision medicine interventions, including n-of-1 therapies, pharmacogenomics, gene therapies, and gene editing technologies
- Patient and family preferences, risk perceptions, and decision making related to novel genomic therapies
- Innovative payment, reimbursement, and financing models for high-cost genomic and precision medicine interventions

Please direct any content-related questions to Guest Editors **Sarah Wordsworth, PhD** (sarah.wordsworth@dph.ox.ac.uk), **Hadley Stevens Smith, PhD, MPSA** (hadley.smith@hphci.harvard.edu), or **Dean Regier, PhD** (dean.regier@ubc.ca) or **David Veenstra, PhD, PharmD** (veenstra@uw.edu). Submissions received before **March 1, 2027** will have the best chance of being published in *Value in Health* in 2027.

All invited papers will undergo the journal's peer-review process before the Editors make final decisions about papers to be included in this themed section of *Value in Health*. Authors should submit manuscripts through the journal's online submission system at <https://mc.manuscriptcentral.com/valueinhealth> and be sure to indicate in their cover letter that the paper is to be considered as part of the Genomic and Precision Medicine theme.

www.ispor.org

505 Lawrence Square Blvd South, Lawrenceville, NJ 08648
© 2026 ISPOR – The professional society for health economics and outcomes research

 **ISPOR**
Improving healthcare decisions